Encyclopedia of Clinical Neuropsychology

2018 Edition
| Editors: Jeffrey S. Kreutzer, John DeLuca, Bruce Caplan

Valbenazine

  • Efrain Antonio GonzalezEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-57111-9_9268

Generic Name

Valbenazine

Brand Name

Ingrezza

Class

Central Monoamine-Depleting Agents

Proposed Mechanism(s) of Action

Reversible inhibition of vesicular monoamine transporter 2 (VMAT2), which is a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release from the presynaptic cell.

Indication

Treatment of tardive dyskinesia in adults.

Off Label Use

N/A

Side Effects

Serious

Akathisia, balance disorders/fall, prolonged QT syndrome, especially if co-administered with strong CYP2D6 or CYP3A4 inhibitors, or with patients who are poor CYP2D6 metabolizers.

Common

Anticholinergic effects, headache, vomiting, nausea, arthralgia, somnolence.

References and Readings

  1. Bari, M., Shiwach, R., Jimenez, R., Siegert, S., & O’Brien, C. (2016). Open-label extension of KINECT: A phase 2 study of Valbenazine (NBI-98854) for Tardive Dyskinesia (S27. 001). Neurology, 86(16 Supplement), S27–001.Google Scholar
  2. Free Drug Online and PDA Software. www.epocrates.com
  3. Free Drug Online and PDA Software. www.medscape.com
  4. General Information. www.medscape.com
  5. Hauser, R. A., Factor, S. A., Marder, S. R., Knesevich, M. A., Ramirez, P. M., Jimenez, R., …, O’Brien, C. F. (2017). KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. American Journal of Psychiatry, 174(5), 476–484.PubMedCrossRefPubMedCentralGoogle Scholar
  6. Physicians’ desk reference (71st ed.) (2017). Montvale: Thomson PDR.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.College of PsychologyNova Southeastern UniversityFort LauderdaleUSA
  2. 2.Utah State UniversityLoganUSA